Compounds represented by Formula (I):
or pharmaceutically acceptable salts thereof, are effective as NMDA/NR2B antagonists useful for treating neurological conditions such as, for example, pain, Parkinson's disease, Alzheimer's disease, epilepsy, depression, anxiety, ischemic brain injury including stroke, and other conditions.
[EN] PALLADIUM-CATALYZED ARYLATION OF FLUOROALKYLAMINES<br/>[FR] ARYLATION CATALYSÉE PAR LE PALLADIUM DE FLUOROALKYLAMINES
申请人:UNIV CALIFORNIA
公开号:WO2016183101A1
公开(公告)日:2016-11-17
Methods for synthesizing trifluoroethyl, difluoroethyl, pentafluoropropyl, and difluorophenethyl anilines by palladium-catalyzed coupling of fluoroalkylamines with aryl bromides and aryl chlorides are provided herein. The reaction is conducted with a weaker base such as KOPh in the presence of a catalyst derived from AdBippyPhos and [Pd(allyl)Cl]2. The reactions occur with catalyst loadings less than about 0.50 mol% and tolerate the presence of various functional groups that react with the strong bases that are typically used in Pd-catalyzed C-N cross coupling reactions of aryl halides. The resting state of the catalyst is the phenoxide complex, (BippyPhosPd(Ar)OPh); due to the electron-withdrawing property of the fluoroalkyl substituent, the turn-over limiting step of the reaction is reductive elimination to form the C-N bond.
The invention provides novel inhibitors of IAP that are useful as therapeutic agents for treating malignancies where the compounds have the general formula I:
wherein A, Q, X
1
, X
2
, Y, R
1
, R
2
, R
3
, R
4
, R
4
′, R
5
, R
6
and R
6
′ are as described herein.
Compounds represented by Formula (I) or pharmaceutically acceptable salts thereof, are effective as NMDA/NR2B antagonists useful for treating neurological conditions such as, for example, pain, Parkinson's disease, Alzheimer's disease, epilepsy, depression, anxiety, ischemic brain injury including stroke, and other conditions.